Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression
Abstract
Ketamine and other NMDA (N-methyl-D-aspartate) antagonists produce fast-acting antidepressant-like effects, although the underlying mechanism is unclear. Furthermore, high affinity NMDA antagonists such as ketamine are associated with psychotomimetic effects. To date the link between the antidepressant and psychotomimetic effects of ketamine has not been explored. We examined the relationship between the antidepressant and psychotomimetic effects of a single ketamine infusion in subjects diagnosed with major depressive disorder.
METHODS:
In a double-blind, cross-over, placebo-controlled, two weeks clinical trial we studied the effects of ketamine (0.54 mg/kg within 30 min) in a group of 27 hospitalized depressive patients.
RESULTS:
Higher intensity of psychotomimetic symptoms, measured using BPRS, during ketamine administration correlated with alleviation in mood ratings during the following week with maximum on day seven. Ketamine was superior to placebo in all visits (day 1, 4, and 7) assessed by MADRS with effect size (Cohen´s d) of 0.62, 0.57, and 0.44 respectively. There was no significant correlation between ketamine and nor-ketamine plasma levels and MADRS score change at any study time point.
CONCLUSION:
The substantial relationship between ketamine’s antidepressant and psychotomimetic effects was found. This relationship could be mediated by the initial steps of ketamine’s action, trough NMDA receptors, shared by both ketamine’s clinical effects.
Sos, P., Klirova, M., Novak, T., Kohutova, B., Horacek, J., & Palenicek, T. (2013). Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinology Letters, 34(4), 287-293.
Link to full text
Entheogens, Society & Law takes a major step towards a comprehensive understanding of the human condition, elucidating how empathy, meaning and purpose emerge from three intersecting areas of human life: biology, consciousness and culture.
Mystic Chemist begins at the start of the twentieth century, in the Swiss town of Basel which is evolving from a popular health spa into a major industrial city. The story concludes more than a century later, after celebrating Albert Hofmann’s 100th birthday. It tells the unique story of a soon to be famous scientist, highlighting his academic journey, his research at Sandoz and then, as the discoverer of LSD, his meetings and interactions with illustrious writers, artists and thinkers, from all over the world, whose common interest is a fascination with the new wonder-drug. Luminaries like Aldous Huxley, Timothy Leary and Richard Alpert appear on the scene and Hofmann begins a prolific correspondence with them and other interested parties. Sometimes he sends a sample, other times he hears of their “trips” on LSD or other psychedelic substances, like mescaline or psilocybin. From the beginning he takes a positive view towards efforts by physicians and psychotherapists to include LSD in new approaches to the treatment of illnesses. He sees the “psychedelic” potential of this “wonder drug” as beneficial to all. And he expresses his conviction that mystical experiences and trips to other worlds of consciousness are the best preparation for the very last journey he and every one of us well must eventually make. At the age of 102, Albert Hofmann dies at home. His vitality and open mindedness stay with him until his last breath. The life of Albert Hofmann, the Mystic Chemist, is a testimony to how one can reach a great age all the while remaining physically and mentally fit and spiritually aware. Mystic Chemist: The Life of Albert Hofmann and His Discovery of LSD tells the story of Albert Hofmann’s life and the parallel story of the wonder-drug, LSD. The book runs to 408 pages and contains over 500 color and black and white photographs, illustrations and drawings; some of them never published before. With a foreword by world renowned Czech psychiatrist Stanislav Grof, Mystic Chemist will be published in May 2013, and is available in hardcover and softcover editions.